Important clinical advances in the understanding of Clostridium difficile infection

Current Opinion in Gastroenterology

Volumn 29, Issue 1, 2013, Pages 42-48

  Pacheco, Susan M ^a,b   Johnson, Stuart ^a  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acid suppression therapy; Clostridium difficile; fecal microbiota transplantation; fidaxomicin; molecular diagnostics

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFAXIMIN; VANCOMYCIN;

ALLOTRANSPLANTATION; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; COMPARATIVE STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; ENZYME IMMUNOASSAY; EPIDEMIC; FECES MICROFLORA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HEALTHCARE ASSOCIATED INFECTION; HOSPITALIZATION; HUMAN; ILEOSTOMY; IMMUNOASSAY; INFECTION CONTROL; INTENSIVE CARE UNIT; MOLECULAR DIAGNOSIS; MORTALITY; NORTH AMERICA; NUCLEIC ACID AMPLIFICATION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; TOTAL COLON RESECTION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; POLYMERASE CHAIN REACTION; RECURRENCE; RISK FACTORS;

EID: 84871633163     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835a68d4     Document Type: Review

References (51)

1. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-1181.
2. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-713.
3. Loo VG, Bourgault A-M, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703.
4. Black SR, Weaver KN, Jones RC, et al. Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. Infect Control Hosp Epidemiol 2011; 32:897-902.
5. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55:351-357.
6. Schwan C, Stecher B, Tzivelekidis T, et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5:e1000626.
7. Papatheodorou P, Carette JE, Bell GW, et al. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2011; 108:16422-16427.
8. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP Statistical Brief #124. January 2012. Rockville, MD: Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.-gov/ reports/statbriefs/sb124.pdf.
9. United Kingdom. Department of Health. The health and social care act 2008: code of practice on the prevention and control of infections and related guidance. December 2010. http://www.dh.gov.uk/prod-consum-dh/ groups/dh-digitalassets/documents/digitalasset/dh-123923.pdf. [Accessed 1 August 2012]
10. Ontario, Canada. Ministry of Health and Long-term Care. Public Hospitals Act. Hospital Management, RRO 1990, Reg 965. July 2012. http://canlii.ca/t/ 51v7k. [Accessed 1 August 2012]
11. McDonald LC, Lessa F, Sievert D, et al. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:1-6.
12. Kasper AM, Nyazee HA, Yokoe DS, et al. A multicenter study of Clostridium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol 2012; 33:470-476.
13. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and Norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012; 55:216-223.
14. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54:1053-1063.
15. Hun Kim J, Toy D, Muder RR. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol 2011; 32:656-660.
16. Guerrero DM, Nerandzic MM, Jury LA, et al. Clostridium difficile infection in a Department of Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol 2011; 32:513-515.
17. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-447.
18. Drekonja DM, Amundson WH, DeCarolis DD, et al. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011; 124:1081.e1-1081.
19. Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53:1173-1178.
20. Gil Kim Y, Graham DY, Ik Jang B. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease. A case-control analysis matched by propensity score. J Clin Gastroenterol 2012; 46:397-400.
21. Stevens V, Dumyati G, Brown J, van Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011; 20:1035-1042.
22. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of communityassociated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124:276.e1-276.
23. Shing Kwok C, Kobina Arthur A, Ifeanyichukwu Anibueze C, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011-1019.
24. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficileassociated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001-1010.
25. United States. Department of Health and Human Services. Food and Drug Administration. Proton Pump Inhibitors (PPIs)-Drug Safety Communication: Clostridium difficile-associated diarrhea (CDAD) can be associated with stomach acid drugs. February 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm290838.htm. [Accessed 30 July 2012]
26. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS One 2012; 7:e30258.
27. Tenover FC, Novak-Weekley S, Woods CW, et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol 2010; 48:3719-3724.
28. Deshpande A, Pasupuleti V, Rolston DDK, et al. Diagnostic accuracy of realtime polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011; 53:e81-e90.
29. O'Horo JC, Jones A, Sternke M, et al. Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. Mayo Clin Proc 2012; 87:643-651.
30. Lalande V, Barrault L, Wadel S, et al. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol 2011; 49:2714-2716.
31. Boyanton BL Jr, Sural P, Loomis CR, et al. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J Clin Microbiol 2012; 50:640-645
32. Khanna S, Pardi DS, Rosenblatt JE, et al. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. J Clin Gastroenterol 2012. [Epub ahead of print]
33. Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol 2011; 49:2887-2893.
34. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
35. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a doubleblind, noninferiority, randomized controlled trial. Lancet Infect Dis 2012; 12:281-289.
36. Johnson S, Gerding DN, Louie TJ, et al. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012; 56:4043-4045.
37. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66:2850-2855.
38. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354-360.
39. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
40. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-1087.
41. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients. Methodology and results. J Clin Gastroenterol 2012; 46:145-149.
42. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172:191-193.
43. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-1049.
44. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363-372. (Pubitemid 34183887)
45. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage. An alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile-associated disease. Ann Surg 2011; 254:423-429.
46. Patino H, Stevens C, Louie T, et al. Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection. In: Proceedings of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, IL; abstract# K-205a.
47. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
48. Johnson S, Maziade P-J, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012. [Epub ahead of print]
49. Villano SA, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of spores of VP20621, nontoxigenic Clostridium difficile (NTCD) strain M3, in healthy subjects. Antimicrob Agents Chemother 2012; 56:5224-5229.
50. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012; 30: 2245-2249.
51. Tian J-H, Fuhrmann SR, Kluepfel-Stahl S, et al. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012; 30:4249-4258.